Javier Lepe

Dr. Javier Lepe

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2021 in Neuroscience Letters
Verified
Journal Article
Closed access
NLNaomi Lomeli
Naomi Lomeli
JLJavier Lepe
Javier Lepe
KGKalpna Gupta
Kalpna Gupta
DBDaniela A. Bota
Daniela A. Bota

22 October 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZMZahra Motahari
Zahra Motahari
JLJavier Lepe
Javier Lepe
MBMalia R Bautista
Malia R Bautista
CHClay Hoerig
Clay Hoerig
APAshley S Plant-Fox
Ashley S Plant-Fox
DBDaniela A. Bota
Daniela A. Bota
Medulloblastoma is the most common malignant brain tumor in children. It has WNT-driven, SHH-driven/TP53 mutant, SHH-driven/TP53 wildtype, and non-WNT/non-SHH subgroups. MAGMAS (Mitochondrial Associated Granulocyte Macrophage colony-stimulating factor Signaling molecules) encodes a mitochondrial import inner membrane translocase subunit and is responsible for the translocation of matrix proteins across the inner membrane. We previously reported that a small molecule MAGMAS inhibitor, BT9, decreases cell proliferation, migration, and oxidative phosphorylation in adult glioblastoma cell lines. The aim of our study was to investigate whether the chemotherapeutic effect of BT9 can be extended to pediatric medulloblastoma. Methods: DAOY (SHH driven/tp53 mutant) and D425 (non-SHH group 3) were treated with BT9. For in vitro analysis, cell proliferation, death, migration, invasion, and metabolic activity were assessed using MTT assay, TUNEL staining, scratch wound assay, Matrigel invasion chambers, and seahorse assay, respectively. A D425 orthotopic xenograft mouse model was used to evaluate BT9 efficacy in vivo. Results: BT9 treatment resulted in a significant decrease in cell proliferation (DAOY, 24 hours IC50: 3.6 μM, 48 hours IC50: 2.3 μM, 72 hours IC50: 2.1 μM; D425 24 hours IC50: 3.4 μM, 48 hours IC50: 2.2 μM, 72 hours IC50: 2.1 μM) and a significant increase in cell death (DAOY, 24 hours p = 0.0004, 48 hours p<0.0001; D425, 24 hours p = 0.0001, 48 hours p = 0.02). In DAOY cells, 3 μM BT9 delayed migration and significantly reduced DAOY and D425 cell invasion (p < 0.0001). It also modified mitochondrial respiratory function in both medulloblastoma cell lines. Compared to control, however, BT9 administration did not improve survival in a D425 orthotopic xenograft mouse model. Conclusions: Our in vitro data showed BT9 antitumor efficacy in DAOY and D425 cell lines, suggesting that BT9 may represent a promising targeted therapeutic in pediatric medulloblastoma. These data, however, need to be further validated in animal models.

24 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAnna Badner
Anna Badner
EREmily K. Reinhardt
Emily K. Reinhardt
TNTheodore V. Nguyen
Theodore V. Nguyen
NMNicole Midani
Nicole Midani
AMAndrew T. Marshall
Andrew T. Marshall
BCBrian Cummings
Brian Cummings
Human neural stem cells (hNSCs) have potential as a cell therapy following traumatic brain injury (TBI). While various studies have demonstrated the efficacy of NSCs from on-going culture, there is a significant gap in our understanding of freshly thawed cells from cryobanked stocks – a more clinically-relevant source. To address these shortfalls, the therapeutic potential of our previously validated Shef-6.0 human embryonic stem cell (hESC)-derived hNSC line was tested following long-term cryostorage and thawing prior to transplant. Immunodeficient athymic nude rats received a moderate unilateral controlled cortical impact (CCI) injury. At 4-weeks post-injury, 6×10 5 freshly thawed hNSCs were transplanted into six injection sites (2 ipsi- and 4 contra-lateral) with 53.4% of cells surviving three months post-transplant. Interestingly, most hNSCs were engrafted in the meninges and the lining of lateral ventricles, associated with high CXCR4 expression and a chemotactic response to SDF1alpha (CXCL12). While some expressed markers of neuron, astrocyte, and oligodendrocyte lineages, the majority remained progenitors, identified through doublecortin expression (78.1%). Importantly, transplantation resulted in improved spatial learning and memory in Morris water maze navigation and reduced risk-taking behavior in an elevated plus maze. Investigating potential mechanisms of action, we identified an increase in ipsilateral host hippocampus cornu ammonis (CA) neuron survival, contralateral dentate gyrus (DG) volume and DG neural progenitor morphology as well as a reduction in neuroinflammation. Together, these findings validate the potential of hNSCs to restore function after TBI and demonstrate that long-term bio-banking of cells and thawing aliquots prior to use may be suitable for clinical deployment. Significance Statement: There is no cure for chronic traumatic brain injury (TBI). While human neural stem cells (hNSCs) offer a potential treatment, no one has demonstrated efficacy of thawed hNSCs from long-term cryobanked stocks. Frozen aliquots are critical for multisite clinical trials, as this omission impacted the use of MSCs for graft versus host disease. This is the first study to demonstrate the efficacy of thawed hNSCs, while also providing support for novel mechanisms of action – linking meningeal and ventricular engraftment to reduced neuroinflammation and improved hippocampal neurogenesis. Importantly, these changes also led to clinically relevant effects on spatial learning/memory and risk-taking behavior. Together, this new understanding of hNSCs lays a foundation for future work and improved opportunities for patient care.

16 May 2023 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
BDBhaskar C. Das
Bhaskar C. Das
JLJavier Lepe
Javier Lepe
MSMohammed Adil Shareef
Mohammed Adil Shareef
NLNaomi Lomeli
Naomi Lomeli
SDSasmita Das
Sasmita Das
DBDaniela A. Bota
Daniela A. Bota

9 June 2026
Verified
Other
Open access
JLJavier Lepe
Javier Lepe
JTJennifer D. Tran
Jennifer D. Tran
NLNaomi Lomeli
Naomi Lomeli
VDVi P. Dang
Vi P. Dang
VNValerie C. Nguyen
Valerie C. Nguyen
DBDaniela A. Bota
Daniela A. Bota
BT9 is effective against TMZ-resistant glioma lines and GSCs, shows synergism with TMZ, and has limited toxicity against HAs. A, U-251 MG, (B) D-54 MG, and (C) normal HAs were treated with BT9 alone for 72 hours, and cell viability was assessed by MTT or XTT assays. D, Panel of 3D synergy plots of U-251 MG, D-54 MG, T98G, resistant cells, and GSCs treated with increasing doses of BT9 ± TMZ for 72 hours. E, Summary graph of HSA synergy scores of all tested glioma cell lines. Scores were calculated using SynFinder+.

9 June 2026
Verified
Other
Open access
JLJavier Lepe
Javier Lepe
JTJennifer D. Tran
Jennifer D. Tran
NLNaomi Lomeli
Naomi Lomeli
VDVi P. Dang
Vi P. Dang
VNValerie C. Nguyen
Valerie C. Nguyen
DBDaniela A. Bota
Daniela A. Bota
Pharmacologic MAGMAS inhibition by BT9 reduces protein trafficking into the mitochondria and increases oxidative stress in glioma lines U-251 MG, T98G, and D-54 MG. A, U-251 MG and D-54 MG were treated with 10 μmol/L BT9 for 24 hours. Mitochondrial lysates were collected, and protein levels of LONP1, ACO2, cytochrome C, COXIV, and TIM23 were assessed by Western blot. TIM23 was used as a loading control. B, U-251 MG and T98G cells were treated with 5 μmol/L BT9 and 2.5 mmol/L of NAC for 24 hours and probed with MitoSOX Red. The median fluorescence intensity (MFI) was determined by flow cytometry (n = 3 technical replicates). C, U-251 MG cells were exposed to 5.6 μmol/L BT9 ± 2.5 mmol/L NAC for 3 days. Cells were then stained with Annexin V/PI and analyzed by flow cytometry to assess early and late apoptosis. Early and late apoptosis events observed for the vehicle were 13%, 5.9% for the NAC control, 30.7% for the BT9-treated cells, and 13.6% for the BT9 and NAC-treated cells. Data representative of one experiment. Data are shown as the mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.